Glenmark Pharmaceuticals' Subsidiary Signs Exclusive Global Licensing Agreement for First-in-Class CD38xBCMAxCD3 Trispecific Antibody ISB 2001
Ichnos Glenmark Innovation (IGl), a step-down wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, and AbbVie have announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001. ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Phase 1 for relapsed/refractory multiple myeloma. The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals is eligible to receive up to $1.925 billion in payments, along with tiered, double-digit royalties on net sales. The U.S. Food & Drug Administration has granted ISB 2001 Orphan Drug Designation and Fast Track Designation for the treatment of relapsed/refractory myeloma patients.
Key Highlights
- Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation, signs an exclusive global licensing agreement with AbbVie for ISB 2001, a first-in-class CD38xBCMAxCD3 trispecific antibody.
- ISB 2001 is currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
- AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.
- Glenmark Pharmaceuticals is eligible to receive up to $1.925 billion in payments, along with tiered, double-digit royalties on net sales.
- ISB 2001 has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food & Drug Administration for the treatment of relapsed/refractory myeloma patients.